Telix Pharmaceuticals Limited (TLX) M&A Call Transcript
Telix Pharmaceuticals Limited (TLX) M&A Call Transcript
Seeking Alpha9/22/2026Neutral
TLX
Telix Pharmaceuticals LimitedNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$3.89B
P/E Ratio
114.50
EPS
$0.10
Beta
0.60
52W High
$13.11
52W Low
$6.28
50-Day MA
$11.31
200-Day MA
$9.60
Dividend Yield
—
Profit Margin
3.76%
Forward P/E
140.85
PEG Ratio
—
About Telix Pharmaceuticals Limited
Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals for cancer and rare diseases in Australia, Belgium, Japan, Switzerland, and the United States. The company is headquartered in North Melbourne, Australia.
Fundamentals
| Revenue (TTM) | $890.78M |
| Gross Profit (TTM) | $423.71M |
| EBITDA | $69.81M |
| Operating Margin | 9.71% |
| Return on Equity | 7.36% |
| Return on Assets | 2.71% |
| Revenue/Share (TTM) | $2.61 |
| Book Value | $1.44 |
| Price-to-Book | 7.85 |
| Price-to-Sales (TTM) | 4.36 |
| EV/Revenue | 4.73 |
| EV/EBITDA | 58.05 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 22.30% |
| Shares Outstanding | $339.78M |
| Float | $273.62M |
| % Insiders | 0.00% |
| % Institutions | 0.98% |
Historical Volatility
HV 10-Day
101.66%
HV 20-Day
78.58%
HV 30-Day
73.18%
HV 60-Day
61.23%
HV Rank
83.3%
Volatility is currently expanding
Analyst Ratings
Consensus ($19.76 target)
5
BuyLatest News
Telix and ITM Join Forces to Create a Radiopharmaceutical Powerhouse
MELBOURNE, Australia and INDIANAPOLIS and MUNICH, Sept. 21, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces it has signed a strategic agreement to lead a merger with ITM Isotope Technologies Munich SE (“ITM”), a global leader in radioisotope production and radiopharmaceutical development.
GlobeNewsWire9/21/2026Neutral
Australia's Telix Pharma agrees to buy Germany's ITM Isotope for about $1.65 billion
Australia's Telix Pharmaceuticals said on Monday it has agreed to acquire Germany-based ITM Isotope Technologies Munich SE for about $1.65 billion on a cash- and debt-free basis.
Reuters9/20/2026Positive
Telix Pharmaceuticals: 'Buy' On Pixclara FDA Approval And TLX591-Tx Part 2 Advancement
Telix Pharmaceuticals is maintained at a “Buy” rating, supported by FDA approval of PIXCLARA and robust pipeline progress in oncology diagnostics and therapeutics. The company achieved the first FDA-approved FET-PET imaging agent for glioma, with potential label expansion into brain metastases via a phase 3 study. Phase 3 programs for TLX250-Tx in ccRCC and TLX591-Tx in mCRPC are advancing, with FDA alignment and promising safety/pharmacokinetic data supporting further development.
Seeking Alpha9/16/2026Positive
Telix Pharmaceuticals Limited (TLX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Telix Pharmaceuticals Limited (TLX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Seeking Alpha9/14/2026Neutral
Telix to Present at the Morgan Stanley 24th Annual Global Healthcare Conference and H.C. Wainwright 28th Annual Global Investment Conference
MELBOURNE, Australia and INDIANAPOLIS, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) advises that Dr. Christian Behrenbruch, Managing Director and Group CEO and Kevin Richardson, CEO, Precision Medicine will present at the upcoming Morgan Stanley 24th Annual Global Healthcare Conference and at the H.C. Wainwright 28th Annual Global Investment Conference, both in New York, NY.
GlobeNewsWire9/9/2026Neutral
Telix Pharmaceuticals Limited (TLX) Q2 2026 Earnings Call Transcript
Telix Pharmaceuticals Limited (TLX) Q2 2026 Earnings Call Transcript
Seeking Alpha8/20/2026Neutral
Telix Pharmaceuticals H1 Earnings Call Highlights
Telix Pharmaceuticals NASDAQ: TLX reported first-half 2026 revenue of $477 million, up 22% from the prior-year period, as demand for its precision medicine imaging products continued to grow. The company said EBITDA increased 146% year over year to $52 million, while net profit after tax rose to $38 million.
MarketBeat8/20/2026Positive
Telix 2026 Half-Year Results: Strong Commercial Execution and Momentum in Late-Stage Pipeline
MELBOURNE, Australia and INDIANAPOLIS, Aug. 20, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces its financial results for the period ended June 30, 2026.
GlobeNewsWire8/20/2026Neutral
Telix to Host R&D Day in New York City on September 22, 2026
MELBOURNE, Australia and INDIANAPOLIS, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today advises that it will host a Research and Development (R&D) Day on Tuesday, September 22, 2026, from 8:30 a.m. to 12:30 p.m. EDT in New York City.
GlobeNewsWire8/5/2026Neutral
Turn research into an automated options-selling system
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on TLX and any ticker you trade — then tracks every position and per-strategy win rate.
More HEALTHCARE Stocks
Data last updated: 9/26/2026